COVID-19Given past experience with widespread viral infections, for example influenza, we expected that SARS-CoV-2 would create a large number of de novo cases of immune thrombocytopenia (ITP). Perhaps a silver lining on the cloud of SARSCoV-2 is that for patients with ITP, the virus is ...
Multiple studies have highlighted dysregulation of complex networks of peripheral blood immune responses in COVID-19, using single-cell RNA-sequencing (scRNA-seq) analysis5,6,7,8,9,10,11,12,13,14. Monocytes5,6,7,8,9, antigen-presenting cells10, natural killer (NK) cells5,6,11, T cells...
Cancer patient management in the context of the COVID-19 pandemic There are two emerging risks for cancer patients: a 3-fold greater infection risk than in the general population (associated with poor prognosis and greater mortality) and the risk of delayed access to diagnosis, current care and...
President Donald Trump keeps claiming without evidence that he is now immune to COVID-19 after having been diagnosed with it less than two weeks ago, but scientists confirmed on Monday that there has been at least one case of reinfection in the U.S. According to a newstudypublished the Lan...
waning of maternal titers was more significant after first com- pared to second trimester maternal vaccination, and both maternal and neonatal immunity would likely be boosted by a third maternal COVID-19 vaccine dose in the third trimester when primary vaccination (or vaccination series) occurs in...
Individuals with active ITP should have platelet counts monitored before and after COVID-19 vaccination; benefits of vaccination outweigh the risk of an exacerbation in the majority of patients. (See 'COVID-19 vaccination' above.)When To Call A ProfessionalCall your doctor if you have had ...
“We look forward to discussing with public health officials a potential strategy for our Johnson & Johnson COVID-19 vaccine, boosting eight months or longer after the primary single-dose vaccination.” Several scientists have raised concerns that individuals who got the J&J shot would need boosters...
proliferated in official public health updates, news stories, and health care centers as experts navigated all the uncertainties of the covid-19 pandemic. now, we know that the virus can affect anyone, but it can lead to particularly risky complications for the most vulnerable people in our ...
community. None of the patients with MIS-C reported having a preceding COVID-19-like illness before hospitalization; thus, DPoS refers to the days after onset of the symptoms that prompted hospitalization. Differential immune profiles at the time of hospitalization could aid in establishing diagnosis...
Comorbidities are risk factors for development of severe coronavirus disease 2019 (COVID-19). However, the extent to which an underlying comorbidity influences the immune response to severe acute respiratory syndrome coronavirus 2 remains unknown. Objective Our aim was to investigate the complex interrel...